Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 2, 1999, Pages 527-532

  Baldelli, Roberto ^a   Ferretti, Elisabetta ^b   Jaffrain Rea, Marie Lise ^b   Iacobellis, Gianluca ^a   Minniti, Giuseppe ^a   Caracciolo, Barbara ^a   Moroni, Carlo ^a   Cassone, Rosario ^a   Gulino, Alberto ^a   Tamburrano, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DOPPLER ECHOGRAPHY; DRUG EFFECT; DRUG SCREENING; FEMALE; HEART HEMODYNAMICS; HORMONAL THERAPY; HUMAN; MALE; PRIORITY JOURNAL; SLOW RELEASE FORMULATION;

ACROMEGALY; ADULT; AGED; DELAYED-ACTION PREPARATIONS; FEMALE; HEART DISEASES; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HUMAN GROWTH HORMONE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PEPTIDES, CYCLIC; SOMATOSTATIN; VENTRICULAR FUNCTION, LEFT;

EID: 0033054602     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.2.527     Document Type: Article

References (37)

1. 1. Kahaly G, Stover C, Beyer J, Mohr-Kahaly S. 1992 Relation of endocrine and cardiac findings in acromegalics. J Endocrinol Invest. 15:13-18.
2. 2. Lopez-Velasco R, Escobar-Morreale HF, Vega B, et al. 1997 Cardiac involvement in acromegaly: specific cardiomyopathy or consequence of systemic hypertension? J Clin Endocrinol Metab. 82:1047-1053.
3. 3. Colao A, Merola B, Ferone D, Lombardi G. 1997 Acromegaly. J Clin Endocrinol Metab. 82:2777-2781.
4. 4. Saccà L, Cittadini A, Fazio S. 1994 Growth hormone and the heart. Endocr Rev. 15:555-572.
5. 5. Fazio S, Cittadini A, Sabatini D, Merola B, Colao AM, Biondi B. 1993 Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J. 14:26-33.
6. 6. Just H, Nieschlag E, Nicolescu RF, Kroger FJ, Overzier C. 1994 Cardiac function in acromegaly. A clinical and hemodynamic study. Acta Cardiol. 29:89-103.
7. 7. Hayward RP, Emanuel RW, Nabarro JDN. 1987 Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med. 237:41-58.
8. 8. Lieberman SA, Hoffman AR. 1990 Sequelae to acromegaly: reversibility with treatment of the primary disease. Horm Metab Res. 22:313-318.
9. 9. Lie JT, Grossman SJ. 1980 Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 100:41-52.
10. 10. Nabarro JDN. 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512.
11. 11. Hradec J, Marek J, Petrasek J. 1988 The nature of cardiac hypertrophy in acromegaly: an echocardiographic study. Cor Vasa. 30:186-199.
12. 12. Hradec J, Marek J, Kral J, Janota T, Poloniecki J, Malik M. 1993 Long-term echocardiographic follow-up of acromegalic heart disease. Am J Cardiol. 72:205-210.
13. 13. Thuesen L, Christensen SE, Weeke G, Orskov H, Henningsen P. 1989 The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol (Oxf) 30:619-625.
14. 14. Lim MJ, Barkan AL, Buda AJ. 1992 Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med. 117:719-726.
15. 15. Pereira JL, Rodriguez-Puras MJ, Leal-Cerro A, et al. 1991 Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest. 14:17-23.
16. 16. Merola B, Cittadini A, Colao AM, et al. 1993 Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab. 77:790-793.
17. 17. Gunal AI, Isik A, Celiker H, et al. 1996 Short-term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections. Heart. 76:418-421.
18. 18. Heron I, Thomas F, Dero M, Gancel A, Ruiz J M, Schatz B. 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 76:721-727.
19. 19. Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian Multicenter Slow Release Lanreotide Study Group. 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. J Clin Endocrinol Metab. 81:2089-2097.
20. 20. Al-Maskari M, Gebbie J, Kendall-Taylor P. 1996 The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly. Clin Endocrinol (Oxf) 45:415-421.
21. 21. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. 1994 Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol. 130:229-234.
22. 22. Morange I, De Boisvilliers F, Chanson P, et al. 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 79:145-151.
23. 23. World Health Organization/International Society of Hypertension. 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. J Hypertens. 22:392-403.
24. 24. Sahn DJ, De Maria A, Kissio J, Weyman A. 1978 The committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiography measurements. Circulation. 58:1072-1083.
25. 25. Minniti G, Jaffrain-Rea ML, Moroni C, et al. 1998 Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin Endocrinol (Oxf) 49:101-106.
26. 26. Reicheck N, Wilson J, St John-Sutton M, Plappert TA, Goldberg S, Hirshfeld JW. 1982 Non-invasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation. 65:99-108.
27. 27. Devereux RB. 1987 Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization and comparison to the other methods. Hypertension. [Suppl 2] 9:19-26.
28. 28. Lombardi G, Colao A, Ferone D, et al. 1996 Cardiovascular aspects in acromegaly: effects of treatment. Metabolism. [Suppl 1] 45:57-60.
29. 29. Mathews LS, Enberg B, Norstedt G. 1989 Regulation of rat growth hormone receptor gene expression. J Biol Chem. 17:9905-9910.
30. 30. Guse AH, Kiess W, Funk B, Kessler U, Berg I, Gercken G. 1992 Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1, 4, 5-triphosphate formation. Endocrinology. 130:145-151.
31. 31. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M. 1993 Insulin-like growth factor-I induced hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 87:1715-1721.
32. 32. Thuesen L, Christensen SE, Weeke J, Orskow H, Henningsen P. 1988 A hyperkinetic heart in uncomplicated acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand. 223:337-343.
33. 33. McNight JA, McCance DR, Hadden DR, et al. 1989 Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly. Clin Endocrinol (Oxf) 31:431-438.
34. 34. Cuocolo A, Nicolai E, Fazio S, Pace L, Maurea S, Cittadini A. 1995 Impaired left ventricular diastolic filling in patients with acromegaly: assessment with radionuclide angiography. J Nucl Med. 36:196-201.
35. 35. Padayatty SJ, Perrins EJ, Belchetz PE. 1996 Octreotide treatment increases exercise capacity in patients with acromegaly. Eur J Endocrinol. 134:554-559.
36. 36. Chanson P, Timsit J, Masquet C, et al. 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med. 113:921-925.
37. 37. Minniti G, Moroni C, Jaffrain-Rea ML, et al. 1998 Prevalence of hypertension in acromegalic patients: clinical measurement vs. 24-hour ambulatory blood pressure monitoring. Clin Endocrinol (Oxf) 48:149-152.